Cures & Capital
Hello and welcome to Cures & Capital - the podcast on value creation in biotech and pharma.
Together, we are going to dive deep into the world of biotech and pharma to tackle the holy grail - how do we improve return on investment from drug innovation and deliver transformative therapies to patients, efficiently and sustainably.
Hosted by Martin Slezak & Simon Birksø
Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.
Podcasting since 2025 • 18 episodes
Cures & Capital
Latest Episodes
How Wall Street Really Values Biotech with Hartaj Singh
How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both art and formula....
•
1:26:40
Advanced Drug Modalities with Jeff Holder & Adam Siebert: From Science to Real-World Impact
In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life...
•
Season 1
•
Episode 17
•
1:06:12
Sheila Gujrathi, MD: How to elevate female leaders and underrepresented voices in biopharma
In this episode of Cures & Capital, Dr. Sheila Gujrathi — biotech entrepreneur, investor, and former CEO of Gossamer Bio — shares her perspective on how to elevate female leaders and underrepresented voices in biopharma.She discusses...
•
1:00:42
Scott Berry on Rethinking Clinical Trials: Bayesian Design, Adaptivity, and Smarter Decisions
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and...
•
Season 1
•
Episode 15
•
1:19:28
Deborah Dunsire on leading in today’s biopharma landscape
In this episode, we talk to Deborah Dunsire, board chair at Neurvati Neurosciences, multiple times board member, and a former CEO of Lundbeck. With more than 3 decades of experience, Deborah has navigated organizations of every size through cha...
•
Season 1
•
Episode 14
•
1:04:59
